Ubrogepant

Medication

About

Thing
Ubrogepant, sold under the trade name Ubrelvy, is a medication used for the acute treatment of migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine.
Ubrogepant
Definition
Ubrogepant, sold under the trade name Ubrelvy, is a medication used for the acute treatment of migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine.
Ubrogepant
Ubrogepant
Ubrogepant, sold under the trade name Ubrelvy, is a medication used for the acute treatment of migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine.

Pronunciation

English

Ubrogepant

Ubrogepant
SpellingUbrogepant
Pronunciation[Ubrogepant]

Mentions

The Food and Drug Administration approved Ubrelvy, the company’s ubrogepant treatment, on Monday. The oral medication is aimed at treating migraines in patients who are unresponsive to common migraine treatments, such as triptans, or are at risk of cardiovascular disorders. Allergan, which anticipated a December approval by the FDA, said Ubrelvy will be available for sale in the U.S. in the first quarter.

The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.

The US Food and Drug Administration on Monday announced the approval of a drug called ubrogepant for the acute treatment of migraine, which could be a new option for people who can't take or don't respond to migraine medications currently on the market.

New to Cofactor?

Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.

See also: